Worldwide Strategies for the Management of BCC and cSCC: Can Immunotherapies Provide Effective Treatment for Your Patients with Non-Melanoma Skin Cancers?

FACULTY

Vishal Anil Patel, MD, FAAD, FACMS
Director of Cutaneous Oncology, GW Cancer Center
Director of Dermatologic Surgery, GW Department of Dermatology
Assistant Professor of Dermatology & Hematology/Oncology
George Washington University School of Medicine & Health Sciences
Washington, DC

Javier Cañueto Álvarez, MD, PhD
High-Risk Skin Cancer Unit
Department of Dermatology
Hospital Universitario de Salamanca
Associate Professor
Faculty of Medicine
University of Salamanca
Salamanca, Spain

PROGRAM OVERVIEW

This interactive global educational activity is designed to help oncologists, pathologists, surgeons, dermatologists, and other healthcare practitioners who care for patients with advanced or metastatic basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC) to improve their knowledge of the disease, best practices for treatment, and the role of immunotherapy in managing non-melanoma skin cancer (NMSC).

TARGET AUDIENCE

This activity is designed to meet the educational needs of global medical oncologists, pathologists, surgeons, dermatologists, and other healthcare practitioners who care for patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Specify the causes and consequences of immune dysfunction that characterize non-melanoma skin cancers (NMSCs)
  • Interpret data from clinical trials supporting the use of immunotherapy for appropriate patients with NMSCs
  • Compare regional/national evidence-based guidance that can be used to develop treatment plans for patients with NMSCs

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in this interactive global educational activity.

NURSING CREDIT INFORMATION

Purpose: This program would benefit nurses involved in the management of patients with advanced or metastatic basal cell or cutaneous squamous cell carcinomas.
CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Vishal Anil Patel, MD, FAAD, FACMS reports that he receives consulting fees from AstraZeneca, AbbVie, Gritstone, Lilly, Regeneron, Sanofi Genzyme, PhD Biosciences. He has reported contracted research (as Principal Investigator) from Bicycle Therapeutics, EpimAb Biotherapeutics, AstraZeneca, Blueprint, BioAtla, AbbVie, has received honoraria from Pfizer, Merck, Janssen, and Regeneron/Sanofi Genzyme, salary received from Regeneron, royalty from Sanofi, receipt of intellectual property/patent holder from Almirall, has served on the speakers bureau for Jounce Therapeutics, and has received fees for Non-CME services received directly from a commercial interest from Science 37, Inc.

Javier Cañueto Álvarez, MD, PhD reports that he has served on speaker’s bureaus for Amgen, Astra Zeneca, Bristol Meyers Squibb, Genentech, Hoffmann-La Roche, Guardant, Jazz, Lilly, and Regeneron Sanofi-Gencym, has contracted research from Genentech, Astra Zeneca, Novartis, Spectrum, Cullinan Oncology, and Takeda, and has served as a consultant for Sanofi-Genzyme, InflaRx, and Hoffman-La Roche.

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
  • Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
  • Debra Gordon, MS, Medical Director for Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
  • Russie Allen, Accreditation and Outcomes Manager for Med Learning Group, has nothing to disclose.
  • Ana Maria Albino, Senior Program Manager for Med Learning Group, has nothing to disclose.
  • Natalie Smith, Program Coordinator for Med Learning Group, has nothing to disclose.
  • Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the enduring activity.
  3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

 

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Scroll to Top

A Special Thank You to All HCPs

Med Learning Group sends its heartful gratitude to all healthcare professionals giving their all, 24/7, during this pandemic, despite the great risks they face. We cannot thank you enough for your courage and selfless service.

Connecting you with our personalized approach to continuing Medical Education

The Linking Approach to Education from Gap Analysis to Outcomes

Med Learning Group, a division of Ultimate Medical Academy, is a full-service accredited medical education company with commendation. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for not only the practitioner, but also the patient. Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature.

Med Learning Group has expertise in developing both live and online activities that are innovative, case-based, interactive and patient-centric in nature, and we focus on applying adult learning theory and principles to our programs. Even more importantly, we understand the nuances of our target audiences and design programs with a grounded understanding of how to educate both specialty audiences and general practitioners.